FBR Capital Starts Achillion Pharmaceuticals (ACHN) at Outperform, $16 PT

September 14, 2016 5:31 PM EDT
Get Alerts ACHN Hot Sheet
Price: $4.04 -0.49%

Rating Summary:
    14 Buy, 3 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 16 | New: 13
Trade ACHN Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

FBR Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform rating and a price target of $16.00.

Analyst Christopher James commented, "We are initiating coverage of Achillion Pharmaceuticals, Inc. (ACHN) with an Outperform rating and a 12-month price target of $16 per share. We see two very clear value creation paths for ACHN investors. The first is with ACH-4471 for several rare diseases driven by disorders of the complement system, which are multi-billiondollar indications. The second path is through hepatitis C virus (HCV), which is partnered with Janssen Pharmaceuticals. Within the complement space, Achillion is developing small molecule factor D inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and atypical hemolytic uremic syndrome (aHUS). By the end of 3Q16, we expect ACH-4471 to complete Phase I development, setting the stage to begin Phase II studies in PNH and C3G this year. Based on company guidance, we expect interim results for ACH-4471 in PNH by year-end. Although we believe the HCV path will be significantly more challenging given the competitive landscape, the collaboration with Janssen has over $900 million in potential milestones and royalties that escalate into the mid-20% range."

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $7.63 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Add Your Comment